Acute intermittent porphyria, often shortened to AIP, is an inherited condition that can cause episodes of severe abdominal pain and nervous system problems. Understanding it requires two kinds of evidence: measurements of chemicals involved in heme production, and genetic testing. These tests answer different questions. An inherited susceptibility does not, by itself, establish that a current illness is a porphyria attack.
A problem in making heme
Heme is a component of hemoglobin, the protein that carries oxygen in red blood cells, and has roles in other proteins throughout the body. Making heme involves several chemical steps, each supported by an enzyme. Porphyrias are a group of conditions in which this process is disrupted, allowing intermediate chemicals to accumulate. Different types can affect the skin, nervous system or both. MedlinePlus Genetics explains the heme pathway and porphyria types.
AIP involves the HMBS gene. A disease-causing change in one copy of this gene reduces the activity of an enzyme in heme production. AIP belongs to the acute porphyrias, which primarily affect the nervous system. Sun-related skin blistering belongs to other forms of porphyria and is not a defining feature of AIP. The specific type therefore matters when interpreting a diagnosis. See the genetic causes and features of porphyria.
Recognizing symptoms without assuming the cause
Acute porphyrias can cause abdominal pain, nausea, constipation, weakness, confusion or seizures. Severe attacks can involve paralysis and breathing problems. Symptoms can develop over hours or days and continue for days or weeks. However, these symptoms overlap with many other illnesses, including much more common conditions. A symptom list cannot establish the diagnosis. MedlinePlus describes symptoms and the role of laboratory testing.
Laboratory results also need interpretation. Porphyrin tests measure substances in blood, urine or stool, with the sample and analysis chosen according to the suspected condition. An increased result may lead to further testing to confirm porphyria and establish its type. A broad report of increased porphyrins is therefore not a complete explanation of someone’s symptoms. Read about porphyrin test results.
What chemical testing and DNA each contribute
When clinicians suspect an AIP attack, investigation begins with biochemical testing, particularly urine porphobilinogen, or PBG. PBG is a chemical made during heme production. Increased urine PBG, interpreted with compatible symptoms and other possible explanations, supports the assessment of an attack. Genetic analysis can then identify the underlying HMBS change and support testing in relatives. GeneReviews describes the diagnostic approach.
The distinction also works in the other direction. If DNA sequencing first identifies a disease-causing HMBS variant, chemical evidence is still needed to establish that symptoms represent an AIP attack. The genetic finding should not automatically become the explanation for every later episode of pain or illness. See GeneReviews on genetic and biochemical confirmation.
Inheritance does not predict an individual future
AIP follows autosomal dominant inheritance: each child of someone with a disease-causing HMBS variant has a 50% chance of inheriting that variant. Many people who inherit it never develop symptoms. This limits prediction of whether attacks will occur, when they might begin or how severe they might be. Testing relatives for a known familial variant can nevertheless support preventive counselling and appropriate surveillance. GeneReviews explains inheritance and family assessment.
Established care and continuing research
Care depends on clinical activity and severity. Acute attacks are commonly treated in hospital. Longer-term care can include reviewing medicine safety, addressing factors associated with attacks and assessing complications involving blood pressure, kidneys or liver. Some people need treatment to reduce future attacks. A genetic result alone does not specify which treatment is appropriate. NIDDK outlines treatment and complication monitoring.
Research continues into ways to prevent attacks and improve symptoms. Clinical studies investigate benefits and harms; participation does not guarantee improvement. A proposed treatment or a trial listing should therefore be distinguished from an established care option. For readers evaluating new findings, the useful questions are who was studied, what outcome changed and whether safety and lasting benefit were adequately assessed. NIDDK distinguishes clinical research from routine treatment.